OCT 0 7 2008

K081010 19192

# SECTION 7.0 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

april 1 2 miles

#### A. Submitter Information

Submitter's Name:

Davol Inc.

Address:

Subsidiary of C. R. Bard, Inc.

100 Sockanossett Crossroad

Cranston, RI 02920

Telephone:

(401) 215-2252

Fax:

(401) 215-2031

Contact Person:

Date of Preparation:

Stephanie Baker March 20, 2008

B. Device Name

Trade Name:

Bard 3DMAX Mesh

Common/Usual Name:

Surgical Mesh

Classification Name:

Surgical Mesh

C. Predicate Device Name

Trade name:

Bard Mesh (Davol Inc.)

Trade name:

Bard 3DMAX Mesh (Davol Inc.)

Trade name:

Usher's Marlex Tubular Mesh (Davol

Inc.)

## D. Device Description

The modified Bard 3DMAX Mesh is anatomically designed to fit the inguinal anatomy. The device is curve shaped and preformed with sealed edges that allow for easier positioning of the device than a traditional flat sheet of mesh in a laparoscopic inguinal hernia repair. The device is constructed of knitted polypropylene monofilaments 7.5 millimeters in diameter. The knit construction allows the mesh to be stretched in both directions in order to accommodate and reinforce tissue defects. The device contains an orientation marker in an M shape with an arrow to facilitate mesh positioning and placement.

K081010 ps 272

#### E. Intended Use

The modified Bard 3DMAX Mesh is a sterile, single use device indicated to reinforce soft tissue where weakness exists e.g. for repair of hernias and chest wall defects. The intended use for the modified device is exactly the same as the predicate devices, 3DMAX Mesh, Bard Mesh and Usher's Marlex Tubular Mesh.

# F. Summary of Similarities and Differences in Technological Characteristics, Performance and Intended Use

The modified 3DMAX Mesh device and the currently marketed 3DMAX Mesh and Bard Mesh devices are all indicated to reinforce soft tissue where weakness exists e.g. for repair of hernias and chest wall defects. Usher's Marlex Tubular Mesh is also indicated for use in hernia repair.

In addition, all products are similar in technological characteristics and performance. The modified 3DMAX Device differs from the currently marketed 3DMAX device in medial marker material only. The medial marker material used in the modified 3DMAX device will be purchased from a different vendor. The main components of the medial marker, polypropylene and Phthalocyaninato(2-) copper dye will remain the same. However, these items will be purchased from a different vendor and extruded to form a dyed polypropylene monofilament. As a result, there may be slight variations in the medial marker material formulation used in the modified device as compared to the currently marketed 3DMAX Mesh medial marker. These slight variations were evaluated through biocompatibility testing as well as laboratory testing.

### G. Performance Data

Biocompatibility testing was performed on the modified 3DMAX device. Testing performed to date indicates that changes made to the 3DMAX device do not impact its biocompatibility profile. In addition, laboratory testing was performed to compare the modified 3DMAX Mesh device to the currently marketed 3DMAX Mesh and Bard Mesh devices. The results show that the modified device is substantially equivalent to the currently marketed predicate devices. Therefore, based on laboratory testing and biocompatibility data, the modified 3DMAX device is safe and effective for its intended use.



OCT 0 7 2008

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Stephanie Baker Senior Regulatory Affairs Associate Davol Incorporated Subsidiary of C.R. Bard, Incorporated 100 Sockanossett Crossroad Cranston, Rhode Island 02920

Re: K081010

Trade/Device Name: Bard 3DMAX Mesh

Regulation Number: 878.3300 Regulation Name: Surgical Mesh

Regulatory Class: II Product Code: FTL Dated: August 6, 2008 Received: August 7, 2008

Dear Ms. Baker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Mark N. Melkerson

Mark M. Milkern

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

# INDICATION FOR USE STATEMENT

Indications for Use: The Bard 3DMAX Mesh is a sterile, single use device indicated to reinforce soft tissue where weakness exists e.g. for repair of hernias

Bard 3DMAX Mesh

510(k) Number (if known):

Device Name:

and chest wall defects.	<b>5</b>
Prescription Use X AND/OR Use	Over-The-Counter
(Part 21 CFR 801 Subpart D) Subpart C)	(21 CFR 801
(PLEASE DO NOT WRITE BELOW THIS LINE-C PAGE IF NEEDED)	CONTINUE ON ANOTHER
Concurrence of CDRH, Office of Devi	ce Evaluation (ODE)
	Neil RP Orden for nen
(Division Sign-Off)	
In <del>fection Control, Dental Devi</del> ces	and Neurological Devices
510(k) Number:	510(k) Number K08(010
	016